Company Analysis Piramal Pharma Limited
1. Summary
Advantages
- Price (118.55 βΉ) is less than fair price (212.32 βΉ)
- The stock's return over the last year (84.19%) is higher than the sector average (38.55%).
Disadvantages
- Dividends (0.0704%) are below the sector average (0.6496%).
- The company's current efficiency (ROE=0%) is lower than the sector average (ROE=3.69%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Piramal Pharma Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.8% | -3.5% | -2.3% |
| 90 days | 14.1% | -2.5% | -5.6% |
| 1 year | 84.2% | 38.6% | 8% |
PPLPHARMA vs Sector: Piramal Pharma Limited has outperformed the "Healthcare" sector by 45.64% over the past year.
PPLPHARMA vs Market: Piramal Pharma Limited has outperformed the market by 76.21% over the past year.
Stable price: PPLPHARMA is not significantly more volatile than the rest of the market on "Bombay Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: PPLPHARMA with weekly volatility of 1.62% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (118.55 βΉ) is lower than the fair price (212.32 βΉ).
Price significantly below the fair price: The current price (118.55 βΉ) is 79.1% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (56.11).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (43.66).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0) is lower than that of the sector as a whole (8.08).
P/BV vs Market: The company's P/BV (0) is lower than that of the market as a whole (6.15).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (17.79).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (8.67).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (4.22).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (15.13).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-17.15%).
5.4. ROE
ROE vs Sector: The company's ROE (0%) is lower than that of the sector as a whole (3.69%).
ROE vs Market: The company's ROE (0%) is higher than that of the market as a whole (-0.3088%).
5.5. ROA
ROA vs Sector: The company's ROA (0%) is lower than that of the sector as a whole (3.44%).
ROA vs Market: The company's ROA (0%) is lower than that of the market as a whole (7.53%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (11.26%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (16.2%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.0704% is below the average for the sector '0.6496%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.0704% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 0.0704% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
